{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:46:51Z","timestamp":1791312411630,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":3790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1046\/j.1524-4733.2003.00215.x","type":"journal-article","created":{"date-parts":[[2004,12,29]],"date-time":"2004-12-29T17:15:49Z","timestamp":1104340549000},"page":"144-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis"],"prefix":"10.1016","volume":"6","author":[{"given":"Celia C.","family":"Kamath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal Maradit","family":"Kremers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vanness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Michael","family":"O'Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa L.","family":"Cabanela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherine E.","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1524-4733.2003.00215.x_bib10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0895-4356(92)90127-9","article-title":"Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986\u20131990","volume":"45","author":"Gabriel","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib30","series-title":"Pain management markets (August 1993)","author":"Frost & Sullivan Market Intelligence","year":"1995"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.1996.03540070021014","article-title":"Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs","volume":"276","author":"Rothschild","year":"1996","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib50","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/1529-0131(200009)43:9<1905::AID-ANR1>3.0.CO;2-P","article-title":"Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines","volume":"43","author":"Anonymous","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/bmj.317.7157.526","volume":"317","author":"Eccles","year":"1998","journal-title":"BMJ"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib70","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib80","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib90","series-title":"2000 drug topics red book","author":"Medical Economics","year":"2000"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4","article-title":"The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs","volume":"41","author":"Maetzel","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib110","first-page":"2635","article-title":"Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis","volume":"27","author":"Ehrich","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib120","series-title":"Vioxx (Rofecoxib) tablets review","author":"Anonymous","year":"1999"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib130","unstructured":"Witter J. Celebrex capsules (Celecoxib). NDA 20\u2013998\/S-009. Washington: Medical Officer Review, Food and Drug Administration, Center for Drug Evaluation and Research, Arthritis Advisory Committee, 2001. p. 1\u201399."},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib140","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib150","series-title":"VIOXX tablets: VIOXX oral suspension (Rofecoxib). VIOXX Gastrointestinal Outcomes Research Study (VIGOR) briefing information. NDA 21\u2013052","first-page":"1","author":"Anonymous","year":"2001"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib160","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib170","series-title":"Celebrex (celecoxib) capsules review: osteoarthritis statistical review","author":"Anonymous","year":"1998"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib180","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","article-title":"Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s","volume":"160","author":"Hernandez-Diaz","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib190","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.315.7119.1333","article-title":"Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study","volume":"315","author":"MacDonald","year":"1997","journal-title":"BMJ"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib200","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3109\/00365529509093304","article-title":"Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates","volume":"30","author":"Hallas","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib210","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1572-0241.1998.00327.x","article-title":"An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen","volume":"93","author":"Lanza","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib220","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/oxfordjournals.aje.a117469","article-title":"Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons","volume":"141","author":"Smalley","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib230","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0895-4356(98)00076-6","article-title":"Comparative safety evaluation of non-narcotic analgesics","volume":"51","author":"Andrade","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib240","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001648-199207000-00008","article-title":"Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study","volume":"3","author":"Garcia","year":"1992","journal-title":"Epidemiology"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib250","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archinte.1995.00430130043005","article-title":"Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years","volume":"155","author":"Lanza","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib260","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","article-title":"Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis","volume":"312","author":"Henry","year":"1996","journal-title":"BMJ"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib270","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib280","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","article-title":"The relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs","volume":"12","author":"Garcia Rodriguez","year":"2001","journal-title":"Epidemiology"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib290","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/art.10604","article-title":"Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population","volume":"46","author":"Rahme","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib300","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(91)90744-A","article-title":"Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding","volume":"337","author":"Laporte","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1046\/j.1524-4733.2003.00215.x_bib310","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0272-6386(96)90571-5","article-title":"Nonrenal toxicities of acetaminophen, aspirin, and nonsteroidal anti-inflammatory agents","volume":"28","author":"Matzke","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib320","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/art.1780360114","article-title":"Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy","volume":"36","author":"Savage","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib330","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/art.1780360904","article-title":"Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee","volume":"36","author":"Williams","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib340","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM199107113250203","article-title":"Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee","volume":"325","author":"Bradley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.287.1.64","article-title":"Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee\u2014a randomized trial","volume":"287","author":"Geba","year":"2001","journal-title":"JAMA"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib360","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X","article-title":"A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee","volume":"44","author":"Pincus","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib370","author":"Pharmacia"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib380","series-title":"US prescribing information for Vioxx [Internet]","author":"Merck & Co","year":"2000"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00044011-199918020-00001","article-title":"The PAIN study: paracetamol, aspirin, and ibuprofen new tolerability study\u2014a large-scale randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia","volume":"18","author":"Moore","year":"1999","journal-title":"Clin Drug Invest"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib400","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F","article-title":"Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population","volume":"43","author":"Rahme","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1046\/j.1524-4733.2003.00215.x_bib410","first-page":"S225","article-title":"Fewer gastrointestinal protective agents, procedures, and hospitalizations with rofecoxib vs. naproxen in the VIGOR (Vioxx Outcomes Research) Study [Abstract]","volume":"43","author":"Bombardier","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib420","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6","article-title":"A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis","volume":"43","author":"Choi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib430","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","article-title":"Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial","volume":"74","author":"Bensen","year":"1999","journal-title":"Mayo Clinic Proc"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib440","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib\/Ibuprofen Comparator Study Group","volume":"160","author":"Day","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib450","series-title":"All urban consumer price index for medical care","author":"US Department of Labor Bureau of Labor Statistics","year":"2001"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib460","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1214\/aoms\/1177703732","article-title":"Robust estimation of a location parameter","volume":"35","author":"Humber","year":"1964","journal-title":"Ann Math Stat"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib470","series-title":"ADP\/context medical fees in the United States","author":"Practice Management Information","year":"2000"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib480","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hec.4730030505","article-title":"Costs, effects and C\/E-ratios alongside a clinical trial","volume":"3","author":"van Hout","year":"1994","journal-title":"Health Econ"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib490","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib500","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0272989X9701700414","article-title":"Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means","volume":"17","author":"Stinnett","year":"1997","journal-title":"Med Decis Making"},{"issue":"Suppl S15","key":"10.1046\/j.1524-4733.2003.00215.x_bib510","first-page":"26","article-title":"Development of an economic model comparing acetaminophen to NSAIDs in the treatment of mild-to-moderate osteoarthritis","volume":"II","author":"Holzer","year":"1996","journal-title":"Am J Managcare"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib520","first-page":"855","article-title":"A strategy for evaluating the novel COX-2 inhibitors versus NSAIDs for arthritis","volume":"34","author":"Motheral","year":"1999","journal-title":"Hospital Form"},{"issue":"Suppl 1","key":"10.1046\/j.1524-4733.2003.00215.x_bib530","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/00019053-200119001-00004","article-title":"An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada","volume":"19","author":"Zabinski","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 1","key":"10.1046\/j.1524-4733.2003.00215.x_bib540","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00019053-200119001-00005","article-title":"Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland","volume":"19","author":"Chancellor","year":"2001","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 2","key":"10.1046\/j.1524-4733.2003.00215.x_bib550","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/rheumatology\/39.suppl_2.51","article-title":"The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis","volume":"39","author":"Haglund","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"10.1046\/j.1524-4733.2003.00215.x_bib560","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/rheumatology\/39.suppl_2.43","article-title":"Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway","volume":"39","author":"Svarvar","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib570","first-page":"1020","article-title":"Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis","volume":"27","author":"Pincus","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib580","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/1529-0131(200107)44:7<1477::AID-ART267>3.0.CO;2-O","article-title":"The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments","volume":"44","author":"Felson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib590","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.653","article-title":"Drug switching patterns among patients taking non-streroidal anti-inflammatory drugs. a retrospective cohort study of a general practitioners database in the United Kingdom","volume":"10","author":"Langman","year":"2001","journal-title":"Pharmacoepidemiol Drug Safety"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib600","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.1780400204","article-title":"Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs","volume":"40","author":"Walker","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib610","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","article-title":"Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study","volume":"359","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib620","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(02)07273-2","article-title":"Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis","volume":"359","author":"Huang","year":"2002","journal-title":"Lancet"},{"key":"10.1046\/j.1524-4733.2003.00215.x_bib630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(02)07272-0","article-title":"Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial","volume":"359","author":"Chan","year":"2002","journal-title":"Lancet"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510601441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301510601441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:10:59Z","timestamp":1761095459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301510601441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S1098301510601441"],"URL":"https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00215.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cost-Effectiveness of Acetaminophen, NSAIDs, and Selective COX-2 Inhibitors in the Treatment of Symptomatic Knee Osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00215.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}